

**Role of Imaging in Screening
and Early Detection of Ovarian Cancer**

ESSAY

Submitted for fulfillment of the requirements of the
Master Degree in Diagnostic Radiology

By

Marwa Anas Abdel-Rahman Haggag
(M.B.B.Ch; Cairo University)

Supervised by

Ass. Prof. Dr. Rasha Mohamed Kamal
Assistant Professor of Radiology
Faculty of Medicine
Cairo University

Ass. Prof. Dr. Hatem Mohamed El Azizy
Assistant Professor of Radiology
Faculty of Medicine
Cairo University

Dr. Noha Abdel-Shafy El Said
Lecturer of Radiology
NCI
Cairo University

National Cancer Institute
Cairo University
2008

ABSTRACT

Ovarian cancer is currently the most common leading cause of death among the gynecologic malignancies. Its prevalence in the population, and the fact that diagnosis at an earlier stage leads to markedly improved survival, makes it an ideal candidate for a screening program. However, to date, trials of screening programs have not been shown to have any effect on mortality from the disease and screening presents several challenges. **First**, a distinct precursor lesion for ovarian cancer has not been identified. **Second**, identification of the appropriate groups in the general population to be selected for screening is problematic. **Third**, detection of early stage disease requires developing tests with high sensitivity and specificity.

Trials have incorporated multimodal screening protocols which utilize transvaginal ultrasound and measurement of serum CA125 levels. Either to be use concurrently, or one of them as first line, and the other as second line. Serum CA125 as the first line and transvaginal ultrasound as the secondary line achieved a high specificity and positive predictive value and can positively impact the survival.

Key ward :-

- Role of Imaging in Screening
- Early Detection
- Ovarian Cancer

ACKNOWLEDGMENT

First and foremost thanks are to Allah for allowing me to begin, to go through and to complete this work.

My deepest gratitude is to Dr. **Rasha Mohamed Kamal**, Assistant Professor of radiodiagnosis, faculty of Medicine, Cairo University for her continuous support, meticulous supervision, valuable criticism, complete guidance, and encouragement throughout this work.

I am indebted to Dr. Hatem Moh. El Azizy, Assistant Professor of radiodiagnosis, faculty of Medicine, Cairo University, whose support helped me all the time.

My deepest thanks is to Dr. **Noha Abdel-Shafy El Said**, lecturer of radiodiagnosis, national cancer institute, Cairo University whose outstanding support, stimulating suggestions, and encouragement helped me all the time.

My deep appreciation and thanks to **my professors and colleagues** in the Radiodiagnosis Department and **National Cancer Institute**, Cairo University for their extended support and encouragement.

My heartfelt thanks to all **my family members**, my parents, and my sisters for their assistance, encouragement, patience and support through out my work.

Table of Contents

	Content	Page
1.	List of abbreviations.	I
2.	List of figures.	III
3.	List of tables.	VIII
4.	Introduction and aim of work.	1
5.	Chapter (1): Anatomy.	3
	Anatomy of the ovaries.	3
	Sonographic appearance of the ovaries.	12
	Transvaginal color Doppler sonography.	16
	Three dimensional ultrasound.	18
	PET and PET CT appearance of ovaries.	18
	CT scan of the normal ovaries.	19
	MRI appearance of normal ovaries.	21
6.	Chapter (2): Pathology of ovarian cancer.	24
	Epidemiology of ovarian cancer.	24
	Risk factors of ovarian cancer.	24
	Classification of ovarian tumors and pathological features.	25
	Patterns of spread of malignant ovarian lesion.	44
	Staging of malignant ovarian tumors.	45
7.	Chapter (3): Screening and early detection of ovarian cancer.	46
	Introduction.	46
	Progress and challenges in ovarian cancer screening.	47
	Target group.	47
	Screening trials.	49
	Recommendations.	50

8.	Chapter (4): Role of imaging and radiological features.	52
	Role of different imaging modalities in screening of ovarian cancer.	52
	The radiographic features of different types of ovarian cancer.	64
	Role of imaging in staging.	83
	Differential diagnosis of malignant ovarian mass lesions.	93
	Key imaging features in differential diagnosis.	124
9.	Summary.	126
10.	References.	130
11.	Arabic summary.	

List of Abbreviation

AFP	Alpha-fetoprotein.
AP	Antroposterior.
BRCA1	Breast cancer gene 1.
BRCA2	Breast cancer gene 2.
CA125	Cancer antigen 125.
CT	Computed Tomography.
Ed	Editor.
Edn	Edition.
Eds	Editors.
EOC	Epithelial ovarian cancer.
FDG	Fluoro-2-deoxy-D-glucose.
Fig.	Figure.
FIGO	International Federation of Gynecology and Obstetrics.
FLASH	Fast low-angle shot.
FSE	Fast Spin Echo.
GCT	Germ Cell tumor.
HCG	Human chorionic gonadotrophin.
NPV	Negative predictive value.
OC	Ovarian cancer.
MOE	Massive ovarian edema.
MR	Magnetic Resonance.
MRI	Magnetic Resonance Imaging.
PBSO	Prophylactic bilateral salpingo-oophorectomy.
PCOS	Polycystic ovarian syndrome.
PET	Positron Emission Tomography.
PI	Pulsatility index.
PID	Pelvic inflammatory disease.
PPV	Positive predictive value.

RI	Resistive index.
RMI	Risk of malignancy index.
S2	Sacral segment 2.
S3	Sacral segment 3.
S4	Sacral segment 4.
SE	Spin Echo.
SDs	Standard deviations.
SGE	Gadolinium-enhanced fat-suppressed.
SI	Signal intensity.
STIR	Short time inversion recovery.
SUV	Standardized uptake value.
T	Transverse.
T10	Thoracic 10.
T11	Thoracic 11.
3D	Three dimensional.
3DPD	Three-dimensional power Doppler
TOA	Tubo-ovarian abscess.
TV	Transvaginal.
TVS	Transvaginal ultrasound.
TVCD	Transvaginal color Doppler.
T1WI	T1 weighted images.
T2WI	T2 weighted images.
2DPD	Two-dimensional power Doppler.
U	Ultrasound score.
US	Ultrasound.
WHO	World Health Organization

List of Figures

Number	Title	Page
Figure (1)	Ovarian ligaments.	6
Figure (2)	Histology of the ovary.	6
Figure (3)	Blood supply of the ovary.	9
Figure (4)	Sonographic and Doppler appearance of the ovaries.	13
Figure (5)	Normal CT appearance of ovaries.	20
Figure (6)	Normal MRI appearance of ovaries in different sequences.	23
Figure (7)	Diagram shows cell of origin for each type of ovarian cancer.	26
Figure (8)	Diagram shows natural history of disease.	46
Figure (9)	Contrast enhanced US of serous cystadenocarcinoma.	58
Figure (10)	PET-CT in the corpus luteum, versus, PET and CT scan of left ovarian carcinoma.	63
Figure (11)	MRI appearance ovarian serous psammocarcinoma.	65
Figure (12)	US appearance of serous cystadenocarcinoma tumor.	65
Figure (13)	MRI appearance of serous papillary carcinoma.	66
Figure (14)	US appearance of mucinous cystadenocarcinoma.	66
Figure (15)	MRI appearance of mucinous cystadenocarcinoma.	67

Figure (16)	US appearance of Endometrioid carcinoma.	67
Figure (17)	MRI appearance of endometrioid carcinoma.	69
Figure (18)	US and MRI appearance of clear cell carcinoma.	70
Figure (19)	MRI appearance of clear cell carcinoma.	70
Figure (20)	MRI appearance of adult GCT.	73
Figure (21)	US appearance of granulosa cell tumor.	73
Figure (22)	MRI appearance of sertoli-Leydig cell tumor.	74
Figure (23)	MRI appearance of steroid cell tumor.	76
Figure (24)	MRI appearance of Dysgerminoma.	77
Figure (25)	US, MRI & CT appearances of pure primary ovarian choriocarcinoma.	77
Figure (26)	MRI & US appearances of Immature teratoma.	79
Figure (27)	US appearance of Metastatic disease to the ovary.	81
Figure (28)	MRI appearance of bilateral Krukenberg tumors.	81
Figure (29)	CT shows local spread of ovarian carcinoma.	86
Figure (30)	MRI showing Direct uterine invasion.	86
Figure (31)	CT shows stage III ovarian carcinoma.	87
Figure (32)	CT shows pseudomyxoma peritonei.	87

Figure (33)	CT, MRI & PET show implant on the liver capsule.	89
Figure (34)	Combined PET/CT shows metastases to the left supraclavicular lymph nodes	89
Figure (35)	CT & PET for surgically confirmed para-aortic lymph node metastasis.	91
Figure (36)	CT shows Hepatic metastases from stage III versus stage IV ovarian carcinoma.	91
Figure (37)	US shows stage IV ovarian cancer.	92
Figure (38)	MRI appearance of functional cyst.	94
Figure (39)	US appearance of follicular cyst.	94
Figure (40)	US & MRI appearance of corpus luteum cyst.	95
Figure (41)	Spectrum of US appearance of hemorrhagic cysts	95
Figure (42)	MRI appearance of hemorrhagic functional cyst.	97
Figure (43)	US & MRI appearance of theca-luteum cysts.	97
Figure (44)	US & MRI appearance of polycystic ovarian disease.	98
Figure (45)	US appearance of ovarian hyperstimulation.	98
Figure (46)	MRI appearance of ovarian torsion in ovarian hyperstimulation syndrome	100
Figure (47)	Spectrum of US appearances of endometriosis.	100
Figure (48)	Us and MRI appearance of right ovarian endometrioma.	101

Figure (49)	MRI appearance of endometriotic cysts.	101
Figure (50)	US appearance of ovarian torsion.	104
Figure (51)	MRI appearance of ovarian torsion.	104
Figure (52)	US appearance of ectopic pregnancy.	106
Figure (53)	MRI appearance of tubal pregnancy.	106
Figure (54)	PET images of a cystic endometrioma.	107
Figure (55)	MRI appearance of serous cystadenoma.	107
Figure (56)	MRI appearance of mucinous cystadenoma.	109
Figure (57)	US appearance of mucinous cystadenoma.	109
Figure (58)	MRI appearance of brenner tumor	110
Figure (59)	US appearance of fibroma.	110
Figure (60)	MRI appearance of fibroma.	112
Figure (61)	MRI appearance of fibrothecoma.	113
Figure (62)	Spectrum of US appearances of Dermoid tumor.	114
Figure (63)	MRI appearance of Mature cystic teratoma.	114
Figure (64)	US & MRI appearance of pedunculated uterine fibroid.	116
Figure (65)	MRI appearance of subserosal leiomyoma.	116

Figure (66)	MRI appearance of salpingitis.	118
Figure (67)	US appearance of hydrosalpinx.	118
Figure (68)	MRI appearance of bilateral pyosalpinx.	120
Figure (69)	US appearance of tubo-ovarian abscess.	120
Figure (70)	MRI appearance of tubo-ovarian abscess.	122
Figure (71)	US appearance of paraovarian cyst.	122
Figure (72)	MRI appearance of paraovarian cyst.	123
Figure (73)	US appearance of Peritoneal inclusion cyst.	123
Figure (74)	Schematic for characterizing ovarian masses is based on MRI features.	131

List of Tables

Table (1)	Features that help to differentiate serous from mucinous tumors	68
Table (2)	Strategy for diagnosis of ovarian masses with MR imaging.	125

INTRODUCTION

The comprehensive global cancer statistics from the International Agency for Research on Cancer indicate that gynecological cancers accounted for 19% of the 5.1 million estimated new cancer cases (*Sankaranarayanan and Ferlay, 2006*).

Ovarian carcinoma often is called the "silent killer" because the disease usually is not detected until an advanced stage (*Goff et al, 2000*). Ovarian cancer is the most frequent cause of death from gynecological malignancies in the Western world. Most cases of epithelial ovarian cancer are detected at late stages and the resultant overall five-year survival is poor. However, when epithelial ovarian cancer is detected with the disease confined to the ovary the prognosis is favorable (*Varras, 2004*).

Prospective studies have demonstrated that both CA125 and transvaginal ultrasound can detect a significant proportion of preclinical ovarian cancers, and refinements in interpretation of results have improved sensitivity and reduced the false-positive rate of screening. There is preliminary evidence that screening can improve survival, but the impact of screening on mortality from ovarian cancer is still unclear (*Jacobs and Menon, 2004*).

Imaging has become an essential part in the clinical management of patients with ovarian cancer, contributing to tumor detection, characterization, staging, treatment planning, and follow-up. Imaging findings incorporated into the clinical impression assist in creating a treatment plan specific for an individual patient. Advances in cross-sectional imaging and nuclear medicine (PET) have yielded new insights into the evaluation of tumor prognostic factors. A multimodality approach can satisfy the complex imaging needs of a patient with ovarian cancer; however, the success of such

an approach always depends on available resources and on the skills of the physicians involved (*Mironov et al, 2007*).

An optimal screening test with high levels of sensitivity and specificity is essential for early detection of ovarian cancer. Serological screening with serum Ca125 can be used as a first-line screening test. In combination with TVS or color-flow Doppler imaging, this may prove very effective in early detection of ovarian cancer (*Munkarah et al, 2007*).

Application of 3D ultrasonography and power Doppler imaging In patients with "positive" standard ultrasound tests (annual TVS, followed by TVCD in selected cases) represents a novel approach for the early and accurate detection of ovarian cancer through screening (*Kurjak et al, 2005*).

MRI is more specific and accurate than US and Doppler assessment for characterizing adnexal masses. Women who clinically have a relatively low risk of malignancy but who have complex sonographic features may benefit from MRI (*Sohaib et al, 2005*).

Combined PET/CT demonstrates high diagnostic value in identifying primary ovarian cancer in patients with a pelvic mass of unknown origin and risk of malignant index > 150 . It is suggested that PET/CT is the imaging modality of choice when US shows a pelvic tumor and additional information prior to surgery is needed (*Risum et al, 2007*).

Aim of work

To review the role of different imaging modalities in screening and early detection of ovarian cancer and thus decreasing the morbidity and mortality in those cases.